52808 Guselkumab improves perceived stigmatization in moderate-to-severe psoriasis patients, including obese patients and patients with short disease duration: Results from the real-life G-EPOSS study until Week 76

Introduction: Psoriasis patients suffer from both physical disease burden and perceived stigmatization1,2, which represents a component of the psoriasis action plan of the World Health Organization (WHO)3. G-EPOSS, a prospective, German multicenter study takes a holistic view of patientś well-being, including perceived stigmatization, in addition to assessing the effectiveness of guselkumab in patients with moderate- to- severe psoriasis in routine clinical practice.